Serpins: Development for therapeutic applications

Alexandra Lucas, Jordan R. Yaron, Liqiang Zhang, Colin Macaulay, Douglas McFadden

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Citations (Scopus)

Abstract

Serine protease inhibitors, or serpins, function as central regulators for many vital processes in the mammalian body, maintaining homeostasis for clot formation and breakdown, immune responses, lung function, and hormone or central nervous system activity, among many others. When serine protease activity or serpin-mediated regulation becomes unbalanced or dysfunctional, then severe disease states and pathogenesis can ensue. With serpinopathies, genetic mutations lead to inactive serpins or protein aggregation with loss of function. With other disorders, such as sepsis, atherosclerosis, cancer, obesity, and the metabolic syndrome, the thrombotic and thrombolytic cascades and/or inflammatory responses become unbalanced, with excess bleeding and clotting and upregulation of adverse immune responses. Returning overall balance can be engineered through introduction of a beneficial serpin replacement as a therapeutic or through blockade of serpins that are detrimental. Several drugs have been developed and are currently in use and/or in development both to replace dysfunctional serpins and to block adverse effects induced by aberrant protease or serpin actions. With this chapter, we provide a general overview of the development of a virus-derived serpin, Serp-1, and serpin reactive center loop (RCL) peptides, as therapeutics. Serp-1 is a virus-derived serpin developed as a new class of immune modulator. We will use the development of Serp-1 as a general introduction to serpin-based drug development.

Original languageEnglish (US)
Title of host publicationMethods in Molecular Biology
PublisherHumana Press Inc.
Pages255-265
Number of pages11
DOIs
StatePublished - Jan 1 2018

Publication series

NameMethods in Molecular Biology
Volume1826
ISSN (Print)1064-3745

Fingerprint

Serpins
Therapeutics
Viruses
Serine Proteinase Inhibitors
Serine Proteases
Pharmaceutical Preparations
Sepsis
Atherosclerosis
Homeostasis
Peptide Hydrolases
Up-Regulation
Central Nervous System
Obesity

Keywords

  • Clinical trial
  • Drug development
  • Peptides
  • Serine protease inhibitors
  • Serpins

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics

Cite this

Lucas, A., Yaron, J. R., Zhang, L., Macaulay, C., & McFadden, D. (2018). Serpins: Development for therapeutic applications. In Methods in Molecular Biology (pp. 255-265). (Methods in Molecular Biology; Vol. 1826). Humana Press Inc.. https://doi.org/10.1007/978-1-4939-8645-3_17

Serpins : Development for therapeutic applications. / Lucas, Alexandra; Yaron, Jordan R.; Zhang, Liqiang; Macaulay, Colin; McFadden, Douglas.

Methods in Molecular Biology. Humana Press Inc., 2018. p. 255-265 (Methods in Molecular Biology; Vol. 1826).

Research output: Chapter in Book/Report/Conference proceedingChapter

Lucas, A, Yaron, JR, Zhang, L, Macaulay, C & McFadden, D 2018, Serpins: Development for therapeutic applications. in Methods in Molecular Biology. Methods in Molecular Biology, vol. 1826, Humana Press Inc., pp. 255-265. https://doi.org/10.1007/978-1-4939-8645-3_17
Lucas A, Yaron JR, Zhang L, Macaulay C, McFadden D. Serpins: Development for therapeutic applications. In Methods in Molecular Biology. Humana Press Inc. 2018. p. 255-265. (Methods in Molecular Biology). https://doi.org/10.1007/978-1-4939-8645-3_17
Lucas, Alexandra ; Yaron, Jordan R. ; Zhang, Liqiang ; Macaulay, Colin ; McFadden, Douglas. / Serpins : Development for therapeutic applications. Methods in Molecular Biology. Humana Press Inc., 2018. pp. 255-265 (Methods in Molecular Biology).
@inbook{4b972f55a72e44baba246220be660fc4,
title = "Serpins: Development for therapeutic applications",
abstract = "Serine protease inhibitors, or serpins, function as central regulators for many vital processes in the mammalian body, maintaining homeostasis for clot formation and breakdown, immune responses, lung function, and hormone or central nervous system activity, among many others. When serine protease activity or serpin-mediated regulation becomes unbalanced or dysfunctional, then severe disease states and pathogenesis can ensue. With serpinopathies, genetic mutations lead to inactive serpins or protein aggregation with loss of function. With other disorders, such as sepsis, atherosclerosis, cancer, obesity, and the metabolic syndrome, the thrombotic and thrombolytic cascades and/or inflammatory responses become unbalanced, with excess bleeding and clotting and upregulation of adverse immune responses. Returning overall balance can be engineered through introduction of a beneficial serpin replacement as a therapeutic or through blockade of serpins that are detrimental. Several drugs have been developed and are currently in use and/or in development both to replace dysfunctional serpins and to block adverse effects induced by aberrant protease or serpin actions. With this chapter, we provide a general overview of the development of a virus-derived serpin, Serp-1, and serpin reactive center loop (RCL) peptides, as therapeutics. Serp-1 is a virus-derived serpin developed as a new class of immune modulator. We will use the development of Serp-1 as a general introduction to serpin-based drug development.",
keywords = "Clinical trial, Drug development, Peptides, Serine protease inhibitors, Serpins",
author = "Alexandra Lucas and Yaron, {Jordan R.} and Liqiang Zhang and Colin Macaulay and Douglas McFadden",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/978-1-4939-8645-3_17",
language = "English (US)",
series = "Methods in Molecular Biology",
publisher = "Humana Press Inc.",
pages = "255--265",
booktitle = "Methods in Molecular Biology",

}

TY - CHAP

T1 - Serpins

T2 - Development for therapeutic applications

AU - Lucas, Alexandra

AU - Yaron, Jordan R.

AU - Zhang, Liqiang

AU - Macaulay, Colin

AU - McFadden, Douglas

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Serine protease inhibitors, or serpins, function as central regulators for many vital processes in the mammalian body, maintaining homeostasis for clot formation and breakdown, immune responses, lung function, and hormone or central nervous system activity, among many others. When serine protease activity or serpin-mediated regulation becomes unbalanced or dysfunctional, then severe disease states and pathogenesis can ensue. With serpinopathies, genetic mutations lead to inactive serpins or protein aggregation with loss of function. With other disorders, such as sepsis, atherosclerosis, cancer, obesity, and the metabolic syndrome, the thrombotic and thrombolytic cascades and/or inflammatory responses become unbalanced, with excess bleeding and clotting and upregulation of adverse immune responses. Returning overall balance can be engineered through introduction of a beneficial serpin replacement as a therapeutic or through blockade of serpins that are detrimental. Several drugs have been developed and are currently in use and/or in development both to replace dysfunctional serpins and to block adverse effects induced by aberrant protease or serpin actions. With this chapter, we provide a general overview of the development of a virus-derived serpin, Serp-1, and serpin reactive center loop (RCL) peptides, as therapeutics. Serp-1 is a virus-derived serpin developed as a new class of immune modulator. We will use the development of Serp-1 as a general introduction to serpin-based drug development.

AB - Serine protease inhibitors, or serpins, function as central regulators for many vital processes in the mammalian body, maintaining homeostasis for clot formation and breakdown, immune responses, lung function, and hormone or central nervous system activity, among many others. When serine protease activity or serpin-mediated regulation becomes unbalanced or dysfunctional, then severe disease states and pathogenesis can ensue. With serpinopathies, genetic mutations lead to inactive serpins or protein aggregation with loss of function. With other disorders, such as sepsis, atherosclerosis, cancer, obesity, and the metabolic syndrome, the thrombotic and thrombolytic cascades and/or inflammatory responses become unbalanced, with excess bleeding and clotting and upregulation of adverse immune responses. Returning overall balance can be engineered through introduction of a beneficial serpin replacement as a therapeutic or through blockade of serpins that are detrimental. Several drugs have been developed and are currently in use and/or in development both to replace dysfunctional serpins and to block adverse effects induced by aberrant protease or serpin actions. With this chapter, we provide a general overview of the development of a virus-derived serpin, Serp-1, and serpin reactive center loop (RCL) peptides, as therapeutics. Serp-1 is a virus-derived serpin developed as a new class of immune modulator. We will use the development of Serp-1 as a general introduction to serpin-based drug development.

KW - Clinical trial

KW - Drug development

KW - Peptides

KW - Serine protease inhibitors

KW - Serpins

UR - http://www.scopus.com/inward/record.url?scp=85053084917&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053084917&partnerID=8YFLogxK

U2 - 10.1007/978-1-4939-8645-3_17

DO - 10.1007/978-1-4939-8645-3_17

M3 - Chapter

C2 - 30194606

AN - SCOPUS:85053084917

T3 - Methods in Molecular Biology

SP - 255

EP - 265

BT - Methods in Molecular Biology

PB - Humana Press Inc.

ER -